Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ligand Pharmaceuticals (LGND) Net Income (2016 - 2025)

Historic Net Income for Ligand Pharmaceuticals (LGND) over the last 13 years, with Q3 2025 value amounting to $117.3 million.

  • Ligand Pharmaceuticals' Net Income changed N/A to $117.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.6 million, marking a year-over-year change of. This contributed to the annual value of -$4.0 million for FY2024, which is 14216.22% down from last year.
  • Ligand Pharmaceuticals' Net Income amounted to $117.3 million in Q3 2025.
  • In the past 5 years, Ligand Pharmaceuticals' Net Income registered a high of $117.3 million during Q3 2025, and its lowest value of -$42.5 million during Q1 2025.
  • Moreover, its 5-year median value for Net Income was -$4.7 million (2021), whereas its average is -$33923.1.
  • Per our database at Business Quant, Ligand Pharmaceuticals' Net Income soared by 8068.87% in 2021 and then tumbled by 13603.29% in 2022.
  • Quarter analysis of 5 years shows Ligand Pharmaceuticals' Net Income stood at -$2.2 million in 2021, then tumbled by 32.75% to -$3.0 million in 2022, then skyrocketed by 43.58% to -$1.7 million in 2023, then crashed by 1767.15% to -$31.1 million in 2024, then surged by 477.23% to $117.3 million in 2025.
  • Its Net Income stands at $117.3 million for Q3 2025, versus $4.8 million for Q2 2025 and -$42.5 million for Q1 2025.